Online Learning
Free, self-paced HHT courses that earn continuing education credit, available any time through the HHT Continuing Education Hub.
How it works
Earn credit in three steps
Cure HHT is excited to announce the launch of the HHT Continuing Education Hub! Now, providers seeking to further their HHT knowledge can receive continuing education credits when they complete a course. Participation is simple and FREE:
- Register on the HHT Continuing Education Hub
- Enroll in and complete a course
- Receive certificate!
Course catalog
Course Catalog
The following courses are available on the HHT Continuing Education Hub to be viewed at any time.
*You must login to the HHT Continuing Education Hub to enroll and complete courses.
HHT Standards of Care and Diagnostic Tests
Credits: 0.75
Expiration Date: November 10, 2026
Course Title
HHT Standards of Care and Diagnostic Tests
Course Author
Murali Chakinala, MD, FCCP
Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Washington University School of Medicine in St. Louis
St. Louis, MO
Learning Objectives
The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
- Identify the Curacao Criteria for determining the likelihood of HHT in an undiagnosed individual
- Describe the key manifestations of HHT
- Recognize the nature and pattern of epistaxis and mucocutaneous telangiectasias in HHT
- Integrate into clinical practice appropriate screening for visceral AVMs in HHT patients
Target Audience
This activity is designed for physicians and nurses who treat patients with Hereditary Hemorrhagic Telangiectasia (HHT). This activity may also be of interest to physician assistants and pharmacists or anyone who specializes in interventional radiology, radiology, interventional neuroradiology, neurology, pulmonology, gastroenterology, genetics, primary care, pediatrics, hematology, hepatology, otolaryngology, critical care, dentistry, dermatology, or cardiology.
Publication Date
November 10, 2023
Expiration Date
November 10, 2026
Accreditation Information
In support of improving patient care, this activity has been planned and implemented by Cure HHT and Washington University School of Medicine in St. Louis. Washington University School of Medicine in St Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credits Available for this Activity:
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.75 ANCC contact hour.
Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive a maximum of 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.
Planning Committee and Content Reviewers
Murali Chakinala, MD, FCCP (Committee Chair)
Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Washington University School of Medicine in St. Louis
St. Louis, MO
Miles Conrad, MD, MPH
Clinical Professor
Department of Radiology and Biomedical Imaging
Interventional Radiology Section
University of California, San Francisco
San Francisco, CA
Adrienne Hammill, MD, PhD
Associate Professor
Department of Pediatrics, Cancer and Blood Diseases Institute, Division of Hematology
Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine
Cincinnati, OH
Raj Kasthuri, MBBS
Professor of Medicine
Division of Hematology, UNC Blood Research Center
UNC School of Medicine
Chapel Hill, NC
Marianne Clancy, MPA
Executive Director & Senior Director, Strategic Partnerships
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Melissa Dickey, MSN, FNP
Director, National HHT Coordinating Center
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Nolie Krock, MSc
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Disclosure Information
It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and mitigated.
All members of the CME department have nothing to disclose.
Speakers are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis.
These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters’ views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the sponsor for CME credits.
Disclosures:
- Murali Chakinala, MD, FCCP
- Research support/grants from Janssen, Bayer, Medtronic, United Therapeutics, Altavant Sciences, Trio Health Analytics, Acceleron / Merck, Gossamer, Respira Therapeutics, Vaderis Therapeutics, and Cure HHT / DOD.
- Consultant and/or advisory committees for Insmed Incorporated, United Therapeutics, Vaderis Therapeutics, Aerovate, Merck, Liquidia Technologies, Inc., and Janssen.
- Compensation for activities performed from Pulmonary Hypertension Association, Cure HHT Foundation, and Janssen.
- Miles Conrad, MD, MPH
- Consultant and/or advisory committees for Medtronic.
- Adrienne Hammill, MD, PhD
- Research support/grants from Novartis, Merck, Protara, Venthera, Avalo, and Palvella.
- Consultant and/or advisory committees for Novartis, Aytu BioPharma, Inc., Diagonal Therapeutics, Ipsen, and IDEAYA Biosciences.
- Raj Kasthuri, MBBS
- Consultant and/or advisory committees for Pharmacosmos Therapeutics.
- Marianne Clancy, MPA
- No financial relationships to disclose.
- Melissa Dickey, MSN, FNP
- No financial relationships to disclose.
- Nolie Krock, MSc
- No financial relationships to disclose.
All disclosures have been mitigated.
Transparency to Learners:
Cure HHT is the sponsor of a Phase II/III clinical trial for pazopanib. Review by the ACCME has determined Cure HHT is not an ineligible company. This disclosure has been mitigated.
Pulmonary Arteriovenous Malformations Presentation, Evaluation, and Management
Credits: 0.75
Expiration Date: November 10, 2026
Course Title
Pulmonary Arteriovenous Malformations Presentation, Evaluation, and Management
Course Author
Claire Kaufman, MD
Associate Professor of Interventional Radiology, School of Medicine
Associate Director, Pacific Northwest HHT Center of Excellence
Dotter Interventional Institute
Oregon Health & Science University
Portland, OR
Learning Objectives
The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
- Describe the clinical definition of pulmonary arteriovenous malformations (PAVMs)
- Recognize the clinical presentation of PAVMs
- Perform a work-up and evaluation of patients for PAVMs
- Describe endovascular treatment of PAVMs
Target Audience
This activity is designed for physicians and nurses who treat patients with Hereditary Hemorrhagic Telangiectasia (HHT). This activity may also be of interest to physician assistants and pharmacists or anyone who specializes in interventional radiology, radiology, interventional neuroradiology, neurology, pulmonology, gastroenterology, genetics, primary care, pediatrics, hematology, hepatology, otolaryngology, critical care, dentistry, dermatology, or cardiology.
Publication Date
November 10, 2023
Expiration Date
November 10, 2026
Accreditation Information
In support of improving patient care, this activity has been planned and implemented by Cure HHT and Washington University School of Medicine in St. Louis. Washington University School of Medicine in St Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credits Available for this Activity:
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.75 ANCC contact hour.
Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive a maximum of 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.
Planning Committee and Content Reviewers
Murali Chakinala, MD, FCCP (Committee Chair)
Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Washington University School of Medicine in St. Louis
St. Louis, MO
Miles Conrad, MD, MPH
Clinical Professor
Department of Radiology and Biomedical Imaging
Interventional Radiology Section
University of California, San Francisco
San Francisco, CA
Adrienne Hammill, MD, PhD
Associate Professor
Department of Pediatrics, Cancer and Blood Diseases Institute, Division of Hematology
Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine
Cincinnati, OH
Raj Kasthuri, MBBS
Professor of Medicine
Division of Hematology, UNC Blood Research Center
UNC School of Medicine
Chapel Hill, NC
Marianne Clancy, MPA
Executive Director & Senior Director, Strategic Partnerships
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Melissa Dickey, MSN, FNP
Director, National HHT Coordinating Center
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Nolie Krock, MSc
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Disclosure Information
It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and mitigated.
All members of the CME department have nothing to disclose.
Speakers are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis.
These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters’ views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the sponsor for CME credits.
Disclosures:
- Claire Kaufman, MD
- Research support/grants from BSCI.
- Consultant and/or on advisory committees for Medtronic and Fluidx GPX.
- Murali Chakinala, MD, FCCP
- Research support/grants from Janssen, Bayer, Medtronic, United Therapeutics, Altavant Sciences, Trio Health Analytics, Acceleron / Merck, Gossamer, Respira Therapeutics, Vaderis Therapeutics, and Cure HHT / DOD.
- Consultant and/or advisory committees for Insmed Incorporated, United Therapeutics, Vaderis Therapeutics, Aerovate, Merck, Liquidia Technologies, Inc., and Janssen.
- Compensation for activities performed from Pulmonary Hypertension Association, Cure HHT Foundation, and Janssen.
- Miles Conrad, MD, MPH
- Consultant and/or advisory committees for Medtronic.
- Adrienne Hammill, MD, PhD
- Research support/grants from Novartis, Merck, Protara, Venthera, Avalo, and Palvella.
- Consultant and/or advisory committees for Novartis, Aytu BioPharma, Inc., Diagonal Therapeutics, Ipsen, and IDEAYA Biosciences.
- Raj Kasthuri, MBBS
- Consultant and/or advisory committees for Pharmacosmos Therapeutics.
- Marianne Clancy, MPA
- No financial relationships to disclose.
- Melissa Dickey, MSN, FNP
- No financial relationships to disclose.
- Nolie Krock, MSc
- No financial relationships to disclose.
All disclosures have been mitigated.
Transparency to Learners:
Cure HHT is the sponsor of a Phase II/III clinical trial for pazopanib. Review by the ACCME has determined Cure HHT is not an ineligible company. This disclosure has been mitigated.
Managing Bleeding, Iron Deficiency, and Anemia in HHT
Credits: 0.5
Expiration Date: December 12, 2026
Course Title
Managing Bleeding, Iron Deficiency and Anemia in Hereditary Hemorrhagic Telangiectasia
Course Author
Raj Kasthuri, MBBS
Professor of Medicine
Division of Hematology, UNC Blood Research Center
UNC School of Medicine
Chapel Hill, NC
Learning Objectives
The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
- Describe the prevalence and severity of anemia in HHT
- Identify management and treatment options for iron deficiency with and without anemia
- Identify management and treatment options for controlling bleeding in HHT patients
Target Audience
This activity is designed for physicians and nurses who treat patients with Hereditary Hemorrhagic Telangiectasia (HHT). This activity may also be of interest to physician assistants and pharmacists or anyone who specializes in interventional radiology, radiology, interventional neuroradiology, neurology, pulmonology, gastroenterology, genetics, primary care, pediatrics, hematology, hepatology, otolaryngology, critical care, dentistry, dermatology, or cardiology.
Publication Date
December 12, 2023
Expiration Date
December 12, 2026
Accreditation Information
In support of improving patient care, this activity has been planned and implemented by Cure HHT and Washington University School of Medicine in St. Louis. Washington University School of Medicine in St Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credits Available for this Activity:
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.5 ANCC contact hour.
Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive a maximum of 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.
Planning Committee and Content Reviewers
Murali Chakinala, MD, FCCP (Committee Chair)
Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Washington University School of Medicine in St. Louis
St. Louis, MO
Miles Conrad, MD, MPH
Clinical Professor
Department of Radiology and Biomedical Imaging
Interventional Radiology Section
University of California, San Francisco
San Francisco, CA
Adrienne Hammill, MD, PhD
Associate Professor
Department of Pediatrics, Cancer and Blood Diseases Institute, Division of Hematology
Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine
Cincinnati, OH
Raj Kasthuri, MBBS
Professor of Medicine
Division of Hematology, UNC Blood Research Center
UNC School of Medicine
Chapel Hill, NC
Marianne Clancy, MPA
Executive Director & Senior Director, Strategic Partnerships
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Melissa Dickey, MSN, FNP
Director, National HHT Coordinating Center
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Nolie Krock, MSc
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Disclosure Information
It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and mitigated.
All members of the CME department have nothing to disclose.
Speakers are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis.
These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters’ views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the sponsor for CME credits.
Disclosures:
- Raj Kasthuri, MBBS
- Consultant and/or advisory committees for Pharmacosmos Therapeutics.
- Murali Chakinala, MD, FCCP
- Research support/grants from Janssen, Bayer, Medtronic, United Therapeutics, Altavant Sciences, Trio Health Analytics, Acceleron / Merck, Gossamer, Respira Therapeutics, Vaderis Therapeutics, and Cure HHT / DOD.
- Consultant and/or advisory committees for Insmed Incorporated, United Therapeutics, Vaderis Therapeutics, Aerovate, Merck, Liquidia Technologies, Inc., and Janssen.
- Compensation for activities performed from Pulmonary Hypertension Association, Cure HHT Foundation, and Janssen.
- Miles Conrad, MD, MPH
- Consultant and/or advisory committees for Medtronic.
- Adrienne Hammill, MD, PhD
- Research support/grants from Novartis, Merck, Protara, Venthera, Avalo, and Palvella.
- Consultant and/or advisory committees for Novartis, Aytu BioPharma, Inc., Diagonal Therapeutics, Ipsen, and IDEAYA Biosciences.
- Marianne Clancy, MPA
- No financial relationships to disclose.
- Melissa Dickey, MSN, FNP
- No financial relationships to disclose.
- Nolie Krock, MSc
- No financial relationships to disclose.
All disclosures have been mitigated.
Transparency to Learners:
Cure HHT is the sponsor of a Phase II/III clinical trial for pazopanib. Review by the ACCME has determined Cure HHT is not an ineligible company. This disclosure has been mitigated.
HHT Epistaxis Evaluation and Management
Credits: 0.75
Expiration Date: November 10, 2026
Course Title
HHT Epistaxis: Evaluation & Management
Course Author
Jeb Justice, MD, FARS
Associate Professor, Chief, Division of Rhinology and Skull Base Surgery
Associate Residency Program Director
APP Director
Co-Director, University of Florida HHT Center of Excellence
University of Florida
Gainesville, FL
Learning Objectives
The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
- Describe the pathophysiology, manifestations, and diagnostic criteria of HHT.
- Recognize the varied clinical presentation of nasal telangiectasia and epistaxis in HHT.
- Perform an evaluation of epistaxis in HHT patients.
- Describe the Second HHT International Guidelines recommendations for management of HHT epistaxis including topical and systemic medical therapies, as well as surgical therapies and their limitations.
Target Audience
This activity is designed for physicians and nurses who treat patients with Hereditary Hemorrhagic Telangiectasia (HHT). This activity may also be of interest to physician assistants and pharmacists or anyone who specializes in interventional radiology, radiology, interventional neuroradiology, neurology, pulmonology, gastroenterology, genetics, primary care, pediatrics, hematology, hepatology, otolaryngology, critical care, dentistry, dermatology, or cardiology.
Publication Date
November 10, 2023
Expiration Date
November 10, 2026
Accreditation Information
In support of improving patient care, this activity has been planned and implemented by Cure HHT and Washington University School of Medicine in St. Louis. Washington University School of Medicine in St Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credits Available for this Activity:
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.75 ANCC contact hour.
Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive a maximum of 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.
Planning Committee and Content Reviewers
Murali Chakinala, MD, FCCP (Committee Chair)
Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Washington University School of Medicine in St. Louis
St. Louis, MO
Miles Conrad, MD, MPH
Clinical Professor
Department of Radiology and Biomedical Imaging
Interventional Radiology Section
University of California, San Francisco
San Francisco, CA
Adrienne Hammill, MD, PhD
Associate Professor
Department of Pediatrics, Cancer and Blood Diseases Institute, Division of Hematology
Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine
Cincinnati, OH
Raj Kasthuri, MBBS
Professor of Medicine
Division of Hematology, UNC Blood Research Center
UNC School of Medicine
Chapel Hill, NC
Marianne Clancy, MPA
Executive Director & Senior Director, Strategic Partnerships
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Melissa Dickey, MSN, FNP
Director, National HHT Coordinating Center
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Nolie Krock, MSc
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Disclosure Information
It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and mitigated.
All members of the CME department have nothing to disclose.
Speakers are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis.
These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters’ views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the sponsor for CME credits.
Disclosures:
- Jeb Justice, MD, FARS
- Consultant and/or on advisory committees for Medtronic.
- Consultant and/or on advisory committees for 3D Matrix.
- Murali Chakinala, MD, FCCP
- Research support/grants from Janssen, Bayer, Medtronic, United Therapeutics, Altavant Sciences, Trio Health Analytics, Acceleron / Merck, Gossamer, Respira Therapeutics, Vaderis Therapeutics, and Cure HHT / DOD.
- Consultant and/or advisory committees for Insmed Incorporated, United Therapeutics, Vaderis Therapeutics, Aerovate, Merck, Liquidia Technologies, Inc., and Janssen.
- Compensation for activities performed from Pulmonary Hypertension Association, Cure HHT Foundation, and Janssen.
- Miles Conrad, MD, MPH
- Consultant and/or advisory committees for Medtronic.
- Adrienne Hammill, MD, PhD
- Research support/grants from Novartis, Merck, Protara, Venthera, Avalo, and Palvella.
- Consultant and/or advisory committees for Novartis, Aytu BioPharma, Inc., Diagonal Therapeutics, Ipsen, and IDEAYA Biosciences.
- Raj Kasthuri, MBBS
- Consultant and/or advisory committees for Pharmacosmos Therapeutics.
- Marianne Clancy, MPA
- No financial relationships to disclose.
- Melissa Dickey, MSN, FNP
- No financial relationships to disclose.
- Nolie Krock, MSc
- No financial relationships to disclose.
All disclosures have been mitigated.
Transparency to Learners:
Cure HHT is the sponsor of a Phase II/III clinical trial for pazopanib. Review by the ACCME has determined Cure HHT is not an ineligible company. This disclosure has been mitigated.
Management of HHT in Pediatric Patients
Credits: 0.5
Expiration Date: March 28, 2027
Course Title
Management of HHT in Pediatric Patients
Course Author
Adrienne Hammill, MD, PhD
Associate Professor
Department of Pediatrics, Cancer and Blood Diseases Institute, Division of Hematology
Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine
Cincinnati, OH
Learning Objectives
The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
- Understand basic information about the pathogenesis of HHT
- Identify the clinical criteria for determining the diagnosis of HHT
- Describe the ways in which the clinical presentation of HHT differs between adults and children
- Articulate the heightened importance of genetic testing for children
- Apply the current pediatric guidelines for the diagnosis and management of HHT
Target Audience
This activity is designed for physicians and nurses who treat patients with Hereditary Hemorrhagic Telangiectasia (HHT). This activity may also be of interest to physician assistants and pharmacists or anyone who specializes in interventional radiology, radiology, interventional neuroradiology, neurology, pulmonology, gastroenterology, genetics, primary care, pediatrics, hematology, hepatology, otolaryngology, critical care, dentistry, dermatology, or cardiology.
Publication Date
March 28, 2024
Expiration Date
March 28, 2027
Accreditation Information
In support of improving patient care, this activity has been planned and implemented by Cure HHT and Washington University School of Medicine in St. Louis. Washington University School of Medicine in St Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credits Available for this Activity:
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.5 ANCC contact hour.
Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive a maximum of 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.
Planning Committee and Content Reviewers
Murali Chakinala, MD, FCCP (Committee Chair)
Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Washington University School of Medicine in St. Louis
St. Louis, MO
Miles Conrad, MD, MPH
Clinical Professor
Department of Radiology and Biomedical Imaging
Interventional Radiology Section
University of California, San Francisco
San Francisco, CA
Adrienne Hammill, MD, PhD
Associate Professor
Department of Pediatrics, Cancer and Blood Diseases Institute, Division of Hematology
Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine
Cincinnati, OH
Raj Kasthuri, MBBS
Professor of Medicine
Division of Hematology, UNC Blood Research Center
UNC School of Medicine
Chapel Hill, NC
Marianne Clancy, MPA
Executive Director & Senior Director, Strategic Partnerships
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Melissa Dickey, MSN, FNP
Director, National HHT Coordinating Center
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Nolie Krock, MSc
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Disclosure Information
It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and mitigated.
All members of the CME department have nothing to disclose.
Speakers are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis.
These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters’ views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the sponsor for CME credits.
Disclosures:
- Adrienne Hammill, MD, PhD
- Research support/grants from Novartis, Merck, Protara, Venthera, Avalo, and Palvella.
- Consultant and/or advisory committees for Novartis, Aytu BioPharma, Inc., Diagonal Therapeutics, Ipsen, and IDEAYA Biosciences.
- Murali Chakinala, MD, FCCP
- Research support/grants from Janssen, Bayer, Medtronic, United Therapeutics, Altavant Sciences, Trio Health Analytics, Acceleron / Merck, Gossamer, Respira Therapeutics, Vaderis Therapeutics, and Cure HHT / DOD.
- Consultant and/or advisory committees for Insmed Incorporated, United Therapeutics, Vaderis Therapeutics, Aerovate, Merck, Liquidia Technologies, Inc., and Janssen.
- Compensation for activities performed from Pulmonary Hypertension Association, Cure HHT Foundation, and Janssen.
- Miles Conrad, MD, MPH
- Consultant and/or advisory committees for Medtronic.
- Raj Kasthuri, MBBS
- Consultant and/or advisory committees for Pharmacosmos Therapeutics.
- Marianne Clancy, MPA
- No financial relationships to disclose.
- Melissa Dickey, MSN, FNP
- No financial relationships to disclose.
- Nolie Krock, MSc
- No financial relationships to disclose.
All disclosures have been mitigated.
Transparency to Learners:
Cure HHT is the sponsor of a Phase II/III clinical trial for pazopanib. Review by the ACCME has determined Cure HHT is not an ineligible company. This disclosure has been mitigated.
Genetic Counseling and Testing for HHT
Credits: 0.75
Expiration Date: August 13, 2027
Course Title
Genetic Counseling and Testing for HHT
Course Author
Zahra S. Girnary, MS, CGC
Clinical Assistant Professor
Cancer and Adult Genetics | Hereditary Hemorrhagic Telangiectasia
University of North Carolina at Chapel Hill
Chapel Hill, NC
Learning Objectives
The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
- Describe the clinical diagnostic criteria for hereditary hemorrhagic telangiectasia (HHT)
- Understand the molecular causes of HHT and its inheritance
- Identify individuals for genetic testing
- Understand the genetic testing process
- Summarize the benefits/limitations of genetic testing for HHT
Target Audience
This activity is designed for physicians and nurses who treat patients with Hereditary Hemorrhagic Telangiectasia (HHT). This activity may also be of interest to physician assistants and pharmacists or anyone who specializes in interventional radiology, radiology, interventional neuroradiology, neurology, pulmonology, gastroenterology, genetics, primary care, pediatrics, hematology, hepatology, otolaryngology, critical care, dentistry, dermatology, or cardiology.
Publication Date
August 13, 2024
Expiration Date
August 13, 2027
Accreditation Information
In support of improving patient care, this activity has been planned and implemented by Cure HHT and Washington University School of Medicine in St. Louis. Washington University School of Medicine in St Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credits Available for this Activity:
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.75 ANCC contact hour.
Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive a maximum of 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.
Planning Committee and Content Reviewers
Murali Chakinala, MD, FCCP (Committee Chair)
Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Washington University School of Medicine in St. Louis
St. Louis, MO
Miles Conrad, MD, MPH
Clinical Professor
Department of Radiology and Biomedical Imaging
Interventional Radiology Section
University of California, San Francisco
San Francisco, CA
Adrienne Hammill, MD, PhD
Associate Professor
Department of Pediatrics, Cancer and Blood Diseases Institute, Division of Hematology
Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine
Cincinnati, OH
Raj Kasthuri, MBBS
Professor of Medicine
Division of Hematology, UNC Blood Research Center
UNC School of Medicine
Chapel Hill, NC
Marianne Clancy, MPA
Executive Director & Senior Director, Strategic Partnerships
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Melissa Dickey, MSN, FNP
Director, National HHT Coordinating Center
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Nolie Krock, MSc
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Disclosure Information
It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and mitigated.
All members of the CME department have nothing to disclose.
Speakers are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis.
These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters’ views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the sponsor for CME credits.
Disclosures:
- Zahra S. Girnary, MS, CGC
- No financial relationships to disclose.
- Murali Chakinala, MD, FCCP
- Research support/grants from Janssen, Bayer, Medtronic, United Therapeutics, Altavant Sciences, Trio Health Analytics, Acceleron / Merck, Gossamer, Respira Therapeutics, Vaderis Therapeutics, and Cure HHT / DOD.
- Consultant and/or advisory committees for Insmed Incorporated, United Therapeutics, Vaderis Therapeutics, Aerovate, Merck, Liquidia Technologies, Inc., and Janssen.
- Compensation for activities performed from Pulmonary Hypertension Association, Cure HHT Foundation, and Janssen.
- Miles Conrad, MD, MPH
- Consultant and/or advisory committees for Medtronic.
- Adrienne Hammill, MD, PhD
- Research support/grants from Novartis, Merck, Protara, Venthera, Avalo, and Palvella.
- Consultant and/or advisory committees for Novartis, Aytu BioPharma, Inc., Diagonal Therapeutics, Ipsen, and IDEAYA Biosciences.
- Raj Kasthuri, MBBS
- Consultant and/or advisory committees for Pharmacosmos Therapeutics.
- Marianne Clancy, MPA
- No financial relationships to disclose.
- Melissa Dickey, MSN, FNP
- No financial relationships to disclose.
- Nolie Krock, MSc
- No financial relationships to disclose.
All disclosures have been mitigated.
Transparency to Learners:
Cure HHT is the sponsor of a Phase II/III clinical trial for pazopanib. Review by the ACCME has determined Cure HHT is not an ineligible company. This disclosure has been mitigated.
Pulmonary Hypertension in HHT
Credits: 0.5
Expiration Date: September 20, 2027
Course Title
Pulmonary Hypertension in Hereditary Hemorrhagic Telangiectasia (HHT)
Course Author
Ali Ataya, MD
Associate Professor of Medicine
Division of Pulmonary, Critical Care & Sleep Medicine
University of Florida College of Medicine
Gainesville, FL
Learning Objectives
The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
- Recognize the prevalence and types of pulmonary hypertension (PH) in the setting of HHT
- Identify the symptoms and etiology of PH in HHT
- Review the different treatment options of PH in HHT
- Discuss the various challenges of PH-HHT management
Target Audience
This activity is designed for physicians and nurses who treat patients with Hereditary Hemorrhagic Telangiectasia (HHT). This activity may also be of interest to physician assistants and pharmacists or anyone who specializes in interventional radiology, radiology, interventional neuroradiology, neurology, pulmonology, gastroenterology, genetics, primary care, pediatrics, hematology, hepatology, otolaryngology, critical care, dentistry, dermatology, or cardiology.
Publication Date
September 20, 2024
Expiration Date
September 20, 2027
Accreditation Information
In support of improving patient care, this activity has been planned and implemented by Cure HHT and Washington University School of Medicine in St. Louis. Washington University School of Medicine in St Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credits Available for this Activity:
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.5 ANCC contact hour.
Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive a maximum of 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.
Planning Committee and Content Reviewers
Murali Chakinala, MD, FCCP (Committee Chair)
Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Washington University School of Medicine in St. Louis
St. Louis, MO
Miles Conrad, MD, MPH
Clinical Professor
Department of Radiology and Biomedical Imaging
Interventional Radiology Section
University of California, San Francisco
San Francisco, CA
Adrienne Hammill, MD, PhD
Associate Professor
Department of Pediatrics, Cancer and Blood Diseases Institute, Division of Hematology
Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine
Cincinnati, OH
Raj Kasthuri, MBBS
Professor of Medicine
Division of Hematology, UNC Blood Research Center
UNC School of Medicine
Chapel Hill, NC
Marianne Clancy, MPA
Executive Director & Senior Director, Strategic Partnerships
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Melissa Dickey, MSN, FNP
Director, National HHT Coordinating Center
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Nolie Krock, MSc
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Disclosure Information
It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and mitigated.
All members of the CME department have nothing to disclose.
Speakers are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis.
These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters’ views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the sponsor for CME credits.
Disclosures:
- Ali Ataya, MD
- Research support/grants from United Therapeutics, INSMED, GossmarBio, Janssen, and Lungpacer Therapeutics.
- Consultant and/or advisory committees for Savara, Partners Therapeutics, United Therapeutics, Lungpacer Therapeutics, LAM foundation, and PAP foundation.
- Murali Chakinala, MD, FCCP
- Research support/grants from Janssen, Bayer, Medtronic, United Therapeutics, Altavant Sciences, Trio Health Analytics, Acceleron / Merck, Gossamer, Respira Therapeutics, Vaderis Therapeutics, and Cure HHT / DOD.
- Consultant and/or advisory committees for Insmed Incorporated, United Therapeutics, Vaderis Therapeutics, Aerovate, Merck, Liquidia Technologies, Inc., and Janssen.
- Compensation for activities performed from Pulmonary Hypertension Association, Cure HHT Foundation, and Janssen.
- Miles Conrad, MD, MPH
- Consultant and/or advisory committees for Medtronic.
- Raj Kasthuri, MBBS
- Consultant and/or advisory committees for Pharmacosmos Therapeutics.
- Marianne Clancy, MPA
- No financial relationships to disclose.
- Melissa Dickey, MSN, FNP
- No financial relationships to disclose.
- Nolie Krock, MSc
- No financial relationships to disclose.
All disclosures have been mitigated.
Transparency to Learners:
Cure HHT is the sponsor of a Phase II/III clinical trial for pazopanib. Review by the ACCME has determined Cure HHT is not an ineligible company. This disclosure has been mitigated.
HHT in School: Presentation and Management
Credits: 0.5
Expiration Date: August 12, 2029
Course Title
HHT in School: Presentation and Management
Course Authors
Leslie A. Perry, MSN, RN
School Nurse
Hereford High School
Parkton, MD
BVMC Research Coordinator
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Karen L. Smith, RN
Program Coordinator
UNC HHT Center of Excellence
Department of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC
Learning Objectives
The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
- Recognize the clinical manifestations of HHT in children
- Promote the importance of early diagnosis and lifetime management of HHT
- Assess concerns of parents/guardians whose student is returning to school with a diagnosis of HHT
- Make recommendations/write order which will optimize the student’s participation in their academic setting
- Manage the procedures required by the student to be in a school setting
Target Audience
This activity is designed for physicians and nurses who treat patients with Hereditary Hemorrhagic Telangiectasia (HHT). This activity may also be of interest to physician assistants and pharmacists or anyone who specializes in interventional radiology, radiology, interventional neuroradiology, neurology, pulmonology, gastroenterology, genetics, primary care, pediatrics, hematology, hepatology, otolaryngology, critical care, dentistry, dermatology, or cardiology.
Publication Date
August 12, 2026
Expiration Date
August 12, 2029
Accreditation Information
In support of improving patient care, this activity has been planned and implemented by Cure HHT and Washington University School of Medicine in St. Louis. Washington University School of Medicine in St Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credits Available for this Activity:
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.5 ANCC contact hour.
Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive a maximum of 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.
Planning Committee and Content Reviewers
Murali Chakinala, MD, FCCP (Committee Chair)
Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Washington University School of Medicine in St. Louis
St. Louis, MO
Miles Conrad, MD, MPH
Clinical Professor
Department of Radiology and Biomedical Imaging
Interventional Radiology Section
University of California, San Francisco
San Francisco, CA
Adrienne Hammill, MD, PhD
Associate Professor
Department of Pediatrics, Cancer and Blood Diseases Institute, Division of Hematology
Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine
Cincinnati, OH
Raj Kasthuri, MBBS
Professor of Medicine
Division of Hematology, UNC Blood Research Center
UNC School of Medicine
Chapel Hill, NC
Marianne Clancy, MPA
Executive Director & Senior Director, Strategic Partnerships
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Melissa Dickey, MSN, FNP
Director, National HHT Coordinating Center
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Nolie Krock, MSc
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Tania Competiello
Senior Director, National Healthcare Programs
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Crystal Cottrill
National HHT Coordinating Center Grant Manager
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Disclosure Information
It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and mitigated.
All members of the CME department have nothing to disclose.
Speakers are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis.
These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters’ views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the sponsor for CME credits.
Disclosures:
- Leslie A. Perry, MSN, RN
- No financial relationships to disclose.
- Karen L. Smith, RN
- No financial relationships to disclose.
- Murali Chakinala, MD, FCCP
- Research support/grants from Janssen, Bayer, Medtronic, United Therapeutics, Altavant Sciences, Trio Health Analytics, Acceleron / Merck, Gossamer, Respira Therapeutics, Vaderis Therapeutics, and Cure HHT / DOD.
- Consultant and/or advisory committees for Insmed Incorporated, United Therapeutics, Vaderis Therapeutics, Aerovate, Merck, Liquidia Technologies, Inc., and Janssen.
- Compensation for activities performed from Pulmonary Hypertension Association, Cure HHT Foundation, and Janssen.
- Miles Conrad, MD, MPH
- Consultant and/or advisory committees for Medtronic.
- Raj Kasthuri, MBBS
- Consultant and/or advisory committees for Pharmacosmos Therapeutics.
- Marianne Clancy, MPA
- No financial relationships to disclose.
- Melissa Dickey, MSN, FNP
- No financial relationships to disclose.
- Nolie Krock, MSc
- No financial relationships to disclose.
- Tania Competiello
- No financial relationships to disclose.
- Crystal Cottrill
- No financial relationships to disclose.
All disclosures have been mitigated.
Transparency to Learners:
Cure HHT is the sponsor of a Phase II/III clinical trial for pazopanib. Review by the ACCME has determined Cure HHT is not an ineligible company. This disclosure has been mitigated.
Clinical Manifestations of Hepatic AVMs and Treatment of High Output Heart Failure
Credits: 0.5
Expiration Date: August 12, 2029
Course Title
Clinical Manifestations of Hepatic AVMs and Treatment of High-Output Heart Failure
Course Author
Peter Hountras, MD
Assistant Professor University of Colorado
Pulmonary & Critical Care Medicine
Learning Objectives
The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
- Recognize the clinical manifestations and diagnostic findings associated with hepatic arteriovenous malformations (AVMs) and high-output cardiac failure (HOCF).
- Evaluate patients with hepatic AVMs and HOCF to determine the severity of cardiac dysfunction and the need for medical or procedural intervention.
- Apply current treatment strategies for HOCF related to hepatic AVMs, including the appropriate use of intravenous bevacizumab.
- Develop an individualized management approach for patients with hepatic AVMs and HOCF, including indications for medical therapy, escalation of treatment, and liver transplantation based on current international HHT guidelines.
Target Audience
This activity is designed for physicians and nurses who treat patients with Hereditary Hemorrhagic Telangiectasia (HHT). This activity may also be of interest to physician assistants and pharmacists or anyone who specializes in interventional radiology, radiology, interventional neuroradiology, neurology, pulmonology, gastroenterology, genetics, primary care, pediatrics, hematology, hepatology, otolaryngology, critical care, dentistry, dermatology, or cardiology.
Publication Date
August 12, 2026
Expiration Date
August 12, 2029
Accreditation Information
In support of improving patient care, this activity has been planned and implemented by Cure HHT and Washington University School of Medicine in St. Louis. Washington University School of Medicine in St Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credits Available for this Activity:
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.5 ANCC contact hour.
Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive a maximum of 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.
Planning Committee and Content Reviewers
Murali Chakinala, MD, FCCP (Committee Chair)
Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Washington University School of Medicine in St. Louis
St. Louis, MO
Miles Conrad, MD, MPH
Clinical Professor
Department of Radiology and Biomedical Imaging
Interventional Radiology Section
University of California, San Francisco
San Francisco, CA
Adrienne Hammill, MD, PhD
Associate Professor
Department of Pediatrics, Cancer and Blood Diseases Institute, Division of Hematology
Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine
Cincinnati, OH
Raj Kasthuri, MBBS
Professor of Medicine
Division of Hematology, UNC Blood Research Center
UNC School of Medicine
Chapel Hill, NC
Marianne Clancy, MPA
Executive Director & Senior Director, Strategic Partnerships
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Melissa Dickey, MSN, FNP
Director, National HHT Coordinating Center
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Nolie Krock, MSc
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Tania Competiello
Senior Director, National Healthcare Programs
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Crystal Cottrill
National HHT Coordinating Center Grant Manager
Cure HHT (HHT Foundation International, Inc.)
Monkton, MD
Disclosure Information
It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and mitigated.
All members of the CME department have nothing to disclose.
Speakers are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis.
These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters’ views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the sponsor for CME credits.
Disclosures:
- Peter Hountras, MD
- Research support/grants from Inari and Cure HHT.
- Consultant and/or advisory committees for Merck, United Therapeutics, Imperative Care, Inari, and Johnson & Johnson.
- Murali Chakinala, MD, FCCP
- Research support/grants from Janssen, Bayer, Medtronic, United Therapeutics, Altavant Sciences, Trio Health Analytics, Acceleron / Merck, Gossamer, Respira Therapeutics, Vaderis Therapeutics, and Cure HHT / DOD.
- Consultant and/or advisory committees for Insmed Incorporated, United Therapeutics, Vaderis Therapeutics, Aerovate, Merck, Liquidia Technologies, Inc., and Janssen.
- Compensation for activities performed from Pulmonary Hypertension Association, Cure HHT Foundation, and Janssen.
- Miles Conrad, MD, MPH
- Consultant and/or advisory committees for Medtronic.
- Raj Kasthuri, MBBS
- Consultant and/or advisory committees for Pharmacosmos Therapeutics.
- Marianne Clancy, MPA
- No financial relationships to disclose.
- Melissa Dickey, MSN, FNP
- No financial relationships to disclose.
- Nolie Krock, MSc
- No financial relationships to disclose.
- Tania Competiello
- No financial relationships to disclose.
- Crystal Cottrill
- No financial relationships to disclose.
All disclosures have been mitigated.
Transparency to Learners:
Cure HHT is the sponsor of a Phase II/III clinical trial for pazopanib. Review by the ACCME has determined Cure HHT is not an ineligible company. This disclosure has been mitigated.
Spread the word
Share the HHT Continuing Education Program flyer with colleagues at your institution or distribute it at your next professional meeting. Email cme@curehht.org to request printed copies.
z